Location Directory

Clinical trials in Birmingham, Alabama

This page shows live ClinicalTrials.gov search results for Birmingham, Alabama, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 9:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1851

Shown on this page

Local exact-city summaries

1851

Based on exact city/state matches in the local index.

Local exact-city recruiting

963

Live official results below use the broader ClinicalTrials.gov location search.

The trial list below is retrieved from the live ClinicalTrials.gov search API for Birmingham, Alabama. Results on this page are currently sorted by Recently updated. Use the filter controls below to narrow by condition, treatment, sponsor, recruitment status, phase, study type, sex, or age.

Showing 1–12 of 1,851 matching trials in Birmingham, AL.

Indexed local directory records.

The summary panels and records below use exact city/state matches from the local directory for Birmingham, AL. Use the filters or full search link when you want broader live ClinicalTrials.gov location matching.

Top conditions in local exact-city summaries

Breast Cancer 34 Obesity 29 Multiple Myeloma 26 Atopic Dermatitis 20 Hypertension 19 Stroke 19

Top sponsors in local exact-city summaries

University of Alabama at Birmingham 340 National Cancer Institute (NCI) 145 Children's Oncology Group 56 Novartis Pharmaceuticals 38 AstraZeneca 37 Eli Lilly and Company 29

Top therapies in local exact-city summaries

Cyclophosphamide 50 Pembrolizumab 40 Carboplatin 36 Nivolumab 33 Radiation Therapy 32 Cisplatin 31

Indexed official records

Open in full search

Conditions: Cardiovascular Risk, Type 2 Diabetes
Interventions: Insulin glargine U-100, Zenagamtide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 45 Years and older
Enrollment: 1,778 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 109
States / cities: Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 91 more

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: EDG-15400 25 mg, EDG-15400 50 mg, Placebo to match EDG-15400 25 mg or 50 mg; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 30 Years to 84 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 25
States / cities: Birmingham, Alabama • Beverly Hills, California • San Diego, California + 20 more

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Interventions: Biospecimen Collection, Cyclophosphamide, Doxorubicin, Durvalumab, Genetic Testing, Mammography, Paclitaxel, Quality-of-Life Assessment; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 3,680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 553
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 425 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Obinutuzumab, Questionnaire Administration, Venetoclax; Procedure · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 623
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 443 more

Conditions: Cutaneous Lichen Planus
Interventions: GIA632, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Birmingham, Alabama • Indianapolis, Indiana

Conditions: Pancreatic Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Endoscopic Ultrasound, Endoscopic Ultrasound-Guided Fine-Needle Aspiration, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Surgical Procedure; Procedure · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 50 Years to 75 Years
Enrollment: 770 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 413
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 294 more

Conditions: Pneumococcal Disease, Vaccine
Interventions: Pneumococcal Vaccine; Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Obesity, Overweight
Interventions: Placebo, Semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 16
States / cities: Birmingham, Alabama • Escondido, California • Huntington Park, California + 13 more

Conditions: Chronic Weight Management, Obesity, Overweight
Interventions: ASC30 tablets A1, Placebo; Drug
Lead sponsor: Ascletis Pharma (China) Co., Limited; Industry
Eligibility: 18 Years and older
Enrollment: 3,003 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 67
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 63 more

Conditions: Chronic Weight Management, Obesity, Overweight, Type 2 Diabetes Mellitus
Interventions: ASC30 tablets A1, Placebo; Drug
Lead sponsor: Ascletis Pharma (China) Co., Limited; Industry
Eligibility: 18 Years and older
Enrollment: 1,560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 85
States / cities: Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 81 more

Conditions: Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor
Interventions: Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, High-Dose-Rate Vaginal Cuff Brachytherapy, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Multigated Acquisition Scan, Paclitaxel, Survey Administration, Trastuzumab/Hyaluronidase-oysk; Procedure · Drug · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 408
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 306 more

Conditions: PH1, Primary Hyperoxaluria Type 1
Interventions: Placebo, YOLT-203; Drug · Genetic
Lead sponsor: YolTech Therapeutics Co., Ltd; Industry
Eligibility: 6 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Clinical trials in Birmingham, Alabama

Filter and sort this location

Top conditions in local exact-city summaries

Top sponsors in local exact-city summaries

Top therapies in local exact-city summaries

Indexed official records

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)